Corticothérapie du choc septique (essai randomisé, en double aveugle comparant l'efficacité de l'administration continue de 300 mg par jour d'hémisuccinate d'hydrocortisone pendant 5 jours à l'administration discontinue en 4 perfusions de 200 mg par jour d'hémissucinate [sic] d'hydrocortisone pendant 7 jours dans la prise en charge des patients en choc septique3)

NICE-BU Médecine Odontologie (060882102) / SudocSudocFranceF

Association of serum lactate with outcome after out-of-hospital cardiac arrest treated with therapeutic hypothermia.

AIMS:Lactate reflects hypoxic insult in many conditions and is considered as a prognosis factor. But, after cardiac arrest, its interest is still debated. Our study aimed to assess the prognosis value of lactate in out-of-hospital cardiac arrest patients treated with therapeutic hypothermia. METHODS:This retrospective observational study included out-of-hospital cardiac arrest patients treated with therapeutic hypothermia in four ICUs. Lactate levels were compared at different times during the first 24 hours according to outcome at ICU discharge and to the type of death (multiorgan or neurologic failure). RESULTS:Two hundred and seventy-two patients were included, 89 good outcome and 183 poor outcome. In the latter group, 171 patients died, from multiorgan failure in 30% and neurologic failure in 70%. Lactate levels were higher in the poor compared to the good outcome patients at admission (5.4 (3.3-9.4) vs. 2.2 (1.5-3.6) mmol/L; p<0.01), 12 hours (2.5 (1.6-4.7) vs. 1.4 (1.0-2.2) mmol/L; p<0.01) and 24 hours (1.8 (1.1-2.8) vs. 1.3 (0.9-2.1) mmol/L; p<0.01). Patients succumbing from multiorgan failure exhibited higher lactate levels compared to those dying from neurologic failure at admission (7.9 (3.9-12.0) vs. 5.2 (3.3-8.8) mmol/L; p<0.01), H12 (4.9 (2.1-8.9) vs. 2.2 (1.4-3.4) mmol/L; p<0.01) and H24 (3.3 (1.8-5.5) vs. 1.4 (1.1-2.5) mmol/L; p<0.01). Initial lactate levels showed an increasing proportion of poor outcome from the first to fourth quartile. CONCLUSIONS:After out-of-hospital cardiac arrest treated with therapeutic hypothermia, lactate levels during the first 24 hours seem linked with ICU outcome. Patients dying from multiorgan failure exhibit higher initial lactate concentrations than patients succumbing from neurological failure

Incidence, Outcomes and Risk Factors of Recurrent Ventilator Associated Pneumonia in COVID-19 Patients: A Retrospective Multicenter Study

Background: High incidence of ventilator associated pneumonia (VAP) has been reported in critically ill patients with COVID-19. Among these patients, we aimed to assess the incidence, outcomes and risk factors of VAP recurrences. Methods: We conducted an observational retrospective study in three French intensive care units (ICUs). Patients admitted for a documented COVID-19 from March 2020 to May 2021 and requiring mechanical ventilation (MV) for ≥48 h were included. The study main outcome was the incidence of VAP recurrences. Secondary outcomes were the duration of MV, ICU and hospital length of stay and mortality according to VAP and recurrences. We also assessed the factors associated with VAP recurrences. Results: During the study period, 398 patients met the inclusion criteria. A total of 236 (59%) of them had at least one VAP episode during their ICU stay and 109 (46%) of these patients developed at least one recurrence. The incidence of VAP recurrence considering death and extubation as competing events was 29.6% (IC = [0.250–0.343]). Seventy-eight percent of recurrences were due to the same bacteria (relapses). Patients with a VAP recurrence had a longer duration of MV as compared with one VAP and no VAP patients (41 (25–56) vs. 16 (8–30) and 10 (5–18) days; p p p = 0.021)). In a multivariate analysis including bacterial co-infection at admission, the use of immunosuppressive therapies and the bacteria responsible for the first VAP episode, the duration of MV was the only factor independently associated with VAP recurrence. Conclusion: In COVID-19 associated respiratory failure, recurrences affected 46% of patients with a first episode of VAP. VAP recurrences were mainly relapses and were associated with a prolonged duration of MV and ICU length of stay but not with a higher mortality. MV duration was the only factor associated with recurrences

Main factors including lactate levels during the first 24 hours associated to poor outcome.

<p>Main factors including lactate levels during the first 24 hours associated to poor outcome.</p

Baseline characteristics of the population and according to outcome at ICU discharge.

<p>Baseline characteristics of the population and according to outcome at ICU discharge.</p

Quartiles of admission lactate levels and percentage of good outcome at ICU discharge.

<p><i>p</i> value <0.001 for comparison between quartiles.</p

Arterial lactate levels during the 24-hours study period in MOF and neurologic failure groups.

<p>Data expressed as median and interquartile range. Comparisons between groups by Mann-Whitney test: * <i>p</i><0.01</p

Main factors associated to the type of death (MOF or neurological failure).

<p>Main factors associated to the type of death (MOF or neurological failure).</p

Causes and Characteristics of Death in Intensive Care Units: A Prospective Multicenter Study

International audienc